{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:57:43Z","timestamp":1792735063607,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.msard.2018.11.021","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T01:03:46Z","timestamp":1542675826000},"page":"157-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"special_numbering":"C","title":["Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis"],"prefix":"10.1016","volume":"29","author":[{"given":"Stuart","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nolting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hicking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2018.11.021_bib0014","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol.(R) Neuroimmunol. Neuroinflammation"},{"issue":"9","key":"10.1016\/j.msard.2018.11.021_bib0033","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.25411","article-title":"Trends in the incidence of nonmelanoma skin cancer in Denmark 1978\u20132007: rapid incidence increase among young Danish women","volume":"127","author":"Birch-Johansen","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.msard.2018.11.021_bib0029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0014-4827(86)90028-5","article-title":"DNA strand breaks, NAD metabolism, and programmed cell death","volume":"164","author":"Carson","year":"1986","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.msard.2018.11.021_bib0015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2018.11.021_bib0003","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","article-title":"MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study","volume":"260","author":"Comi","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.11.021_bib0024","doi-asserted-by":"crossref","unstructured":"Comi, G., Cook, S., Giovannoni, G., et al., 2018. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult. Scleros. Relat. Disord.","DOI":"10.1016\/j.msard.2019.01.038"},{"issue":"5","key":"10.1016\/j.msard.2018.11.021_bib0022","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scleros."},{"issue":"1","key":"10.1016\/j.msard.2018.11.021_bib0028","first-page":"195","article-title":"EP1142: year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5\u00a0mg\/kg in CLARITY and re-treated in CLARITY Extension","volume":"24","author":"Cook","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2018.11.021_bib0016","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.2147\/DDDT.S97956","article-title":"Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations","volume":"10","author":"Dorr","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"issue":"4","key":"10.1016\/j.msard.2018.11.021_bib0008","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study","volume":"3","author":"Freedman","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"5","key":"10.1016\/j.msard.2018.11.021_bib0001","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2018.11.021_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.11.021_bib0006","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.11.021_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1352458517727603","article-title":"Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2018.11.021_bib0010","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2018.11.021_bib0017","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/TCRM.S143509","article-title":"Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program","volume":"13","author":"Havrdova","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"7","key":"10.1016\/j.msard.2018.11.021_bib0021","first-page":"2052","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones","year":"2009","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.msard.2018.11.021_bib0036","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2018.11.021_bib0012","doi-asserted-by":"crossref","DOI":"10.1185\/030079907X233142","article-title":"The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation","volume":"23","author":"Leist","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"S2","key":"10.1016\/j.msard.2018.11.021_bib0013","first-page":"65","article-title":"The mechanism of action of Cladribine and its implications for oral therapy in multiple sclerosis. abstracts from the 23rd annual meeting of the Consortium of Multiple Sclerosis Centers","volume":"11","author":"Leist","year":"2009","journal-title":"Int. J. MS Care"},{"issue":"3","key":"10.1016\/j.msard.2018.11.021_bib0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.11.021_bib0034","unstructured":"Lemtrada CDER Background Package. FDA Center for Drug Evaluation and Research, Peripheral and Central Nervous System Drugs Advisory Committee Meeting. Alemtuzumab (BLA 103948\\5139) Background Package. 2013."},{"key":"10.1016\/j.msard.2018.11.021_bib0023","unstructured":"MAVENCLAD SmPC., https:\/\/www.medicines.org.uk\/emc\/product\/8435, 2017."},{"issue":"2","key":"10.1016\/j.msard.2018.11.021_bib0026","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat. Med."},{"issue":"16 Supplement","key":"10.1016\/j.msard.2018.11.021_bib0009","article-title":"Efficacy of Cladribine tablets as Add-On to IFN-beta therapy in patients with active relapsing MS: final results from the phase II ONWARD study (P3.029)","volume":"86","author":"Montalban","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.11.021_bib0038","unstructured":"Ocrevus CDER Medical Review. FDA Center for Drug Evaluation and Research. Ocrevus (BLA 761053Orig1s000) Medical Review, 12 Sep 2016. 2016."},{"issue":"2","key":"10.1016\/j.msard.2018.11.021_bib0025","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.canep.2011.12.002","article-title":"Comparative incidence of cancer in HIV-AIDS patients and transplant recipients","volume":"36","author":"Oliveira Cobucci","year":"2012","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.msard.2018.11.021_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.msard.2011.08.006","article-title":"Cladribine tablets for relapsing-remitting multiple sclerosis: efficacy across patient subgroups from the phase III CLARITY study","volume":"1","author":"Rammohan","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2018.11.021_bib0032","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-120-9-199405010-00010","article-title":"2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies","volume":"120","author":"Saven","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2018.11.021_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/978-1-4684-1248-2_90","article-title":"Biochemical basis for deoxyadenosine and 2-chlorodeoxyadenosine toxicity to resting human lymphocytes","volume":"195 Pt B","author":"Seto","year":"1986","journal-title":"Adv. Exp. Med. Biol."},{"issue":"8","key":"10.1016\/j.msard.2018.11.021_bib0031","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.4049\/jimmunol.136.8.2839","article-title":"Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes","volume":"136","author":"Seto","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2018.11.021_bib0037","unstructured":"Tecfidera RMP v5. Biogen Idec, Ltd. EU Risk Management Plan BG00012 (Tecfidera, dimethyl fumarate). Version 5, March 2013. 2013."},{"issue":"3","key":"10.1016\/j.msard.2018.11.021_bib0019","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/NXI.0000000000000228","article-title":"Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS","volume":"3","author":"Thomas","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2018.11.021_bib0035","unstructured":"Tysabri FDA Medical Review. FDA Center for Drug Evaluation and Research. Tysabri (BLA 125104\/0) Medical Review, 23 Nov 2004. Part 3, p. 81\u201397. 2004."},{"issue":"10","key":"10.1016\/j.msard.2018.11.021_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/nrneurol.2017.119","article-title":"Cladribine - an old newcomer for pulsed immune reconstitution in MS","volume":"13","author":"Wiendl","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2018.11.021_bib0018","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1517\/14740338.2014.928691","article-title":"Drug safety evaluation of alemtuzumab for multiple sclerosis","volume":"13","author":"Willis","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.msard.2018.11.021_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MOT.0000000000000096","article-title":"Homeostatic expansion as a barrier to lymphocyte depletion strategies","volume":"19","author":"Zwang","year":"2014","journal-title":"Curr. Opin. Organ. Transpl."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:45Z","timestamp":1761900225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":37,"alternative-id":["S2211034818305145"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.021","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}